In a report released today, Sean Lavin from BTIG maintained a Buy rating on Masimo Corp (MASI), with a price target of $137. The company’s shares closed on Friday at $129.62, close to its 52-week high of $130.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 9.8% and a 59.1% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings Inc, Helius Medical Technologies, and Tactile Systems Technology.
Currently, the analyst consensus on Masimo Corp is a Moderate Buy with an average price target of $129.50.
The company has a one-year high of $130 and a one-year low of $81.56. Currently, Masimo Corp has an average volume of 433.7K.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MASI in relation to earlier this year. Most recently, in December 2018, Thomas Samuel Mcclenahan, the EVP & GC of MASI bought 1,000 shares for a total of $22,400.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Masimo Corp. is a medical technology company, which engages in the development and manufacture of non invasive patient monitoring technologies, medical devices, and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography and gas, data download and analytics, and sensors and accessories.